Jim Simons acquired 2.42M Neurocrine Biosciences shares worth $405M. That's 0.56% of their equity portfolio (18th largest holding). The investor owns 2.54% of the outstanding Neurocrine Biosciences stock. The first Neurocrine Biosciences trade was made in Q3 2015. Since then Jim Simons bought shares eighteen more times and sold shares on sixteen occasions. The stake costed the investor $273M, netting the investor a gain of 49% so far.